April 11, 2019 08:24 AM EDT
R&D
Pharma

Re­gen­eron, Al­ny­lam spell out a re­search al­liance that could run be­yond a decade, with bil­lions built in for suc­cess

John Carroll

Editor & Founder

Re­gen­eron $REGN and Al­ny­lam $AL­NY have laid a foun­da­tion for an en­dur­ing R&D al­liance that could go out well past a decade, with bil­lions of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

A service from the Financial Times